Gisadenafil

Research use only, not for human use.

Gisadenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) with an IC50 of 3.6 nM and prevents degradation of cGMP.

Gisadenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) with an IC50 of 3.6 nM and prevents degradation of cGMP.(In Vitro):In COS-7 cells, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in selectivity.(In Vivo):In male Tat-transgenic mice, Gisadenafil (2 mg/kg; i.p.) restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels. Gisadenafil largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline).

UK-369003

Angiogenesis

PDE

Estrogen Receptor/ERR; Human Endogenous Metabolite

——

——

334826-98-1

519.6

C23H33N7O5S

>98% (HPLC)

——

CCOc1ncc(cc1-c1nc2c(CC)n(CCOC)nc2c(=O)[nH]1)S(=O)(=O)N1CCN(CC)CC1

——

(-20℃)

With Ice Pack

≥ 2 years